Gastroenteropancreatic neuroendocrine tumours

The Lancet Oncology

Volumn 9, Issue 1, 2008, Pages 61-72

  Modlin, Irvin M ^a   Oberg, Kjell ^b   Chung, Daniel C ^c   Jensen, Robert T ^d   de Herder, Wouter W ^e   Thakker, Rajesh V ^f   Caplin, Martyn ^g   Delle Fave, Gianfranco ^h   Kaltsas, Greg A ⁱ   Krenning, Eric P ^e   Moss, Steven F ^j   Nilsson, Ola ^k   Rindi, Guido ^l   Salazar, Ramon ^m   Ruszniewski, Philippe ⁿ   Sundin, Anders ^o  

^a YALE UNIVERSITY   (United States)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c HARVARD UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g ROYAL FREE HOSPITAL   (United Kingdom)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ George Genimatas Hospital   (Greece)

^j RHODE ISLAND HOSPITAL   (United States)

^k SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^l UNIVERSITY OF PARMA   (Italy)

^m CATALAN INSTITUTE OF ONCOLOGY   (Spain)

ⁿ BEAUJON HOSPITAL   (France)

^o UPPSALA UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 6 FLUORODOPA F 18; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOPEPTIN; ANTIBIOTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBON 11; CHROMOGRANIN A; CISPLATIN; COPPER 64; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GALLIUM 68; INTERFERON; MITOMYCIN; OCTREOTIDE; SEROTONIN; SOMATOSTATIN DERIVATIVE; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMSIROLIMUS; UNINDEXED DRUG; VATALANIB;

ANTINEOPLASTIC ACTIVITY; CANCER GRADING; CANCER INCIDENCE; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CARCINOGENESIS; CARCINOID; CARCINOID SYNDROME; CHEMOEMBOLIZATION; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GASTRINOMA; GASTROINTESTINAL TRACT SCINTISCANNING; GASTROINTESTINAL TUMOR; HUMAN; INSULINOMA; LIVER METASTASIS; MOLECULAR GENETICS; MONOTHERAPY; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL RATE; SURVIVAL TIME; TUMOR LOCALIZATION; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT;

ANIMALS; CARCINOMA, NEUROENDOCRINE; GASTROINTESTINAL NEOPLASMS; HUMANS; MOLECULAR BIOLOGY; PANCREATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; SOMATOSTATIN; TUMOR MARKERS, BIOLOGICAL;

EID: 37449029464     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70410-2     Document Type: Review

References (78)

1. Barakat M., Meeran K., and Bloom S. Neuroendocrine tumours. Endocr Relat Cancer 11 (2004) 1-18
2. Oberndorfer S. Karzinoide Tumoren des Dünndarms. Frankf Z Pathol 1 (1907) 426-432
3. Pearse A. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem 17 (1969) 303-313
4. Modlin I., Lye K., and Kidd M. A 5-decade analysis of 13 715 carcinoid tumors. Cancer 97 (2003) 934-959
5. US National Cancer Institute. SEER Database. http://seer.cancer.gov/ (accessed Nov 15, 2007).
6. Oberg K., and Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 19 (2005) 753-781
7. US National Cancer Institute. CRISP Database. http://crisp.cit.nih.gov/ (accessed Nov 15, 2007).
8. Rehfeld J. The new biology of gastrointestinal hormones. Physiol Rev 78 (1998) 1087-1108
9. Wang J., Cortina G., Wu S., et al. Mutant neurogenin-3 in congenital malabsorptive diarrhea. N Engl J Med 355 (2006) 270-280
10. Wiedenmann B., John M., Ahnert-Hilger G., and Riecken E. Molecular and cell biological aspects of neuroendocrine tumors of the gastroenteropancreatic system. J Mol Med 76 (1998) 637-647
11. Modlin I., Kidd M., Pfragner R., et al. The functional characterization of normal and neoplastic human enterochromaffin cells. J Clin Endocrinol Metab 91 (2006) 2340-2348
12. Bloom S. Gut hormones (1978), Churchill Livingstone, Edinburgh
13. Kidd M., Modlin I., and Tang L. Gastrin and the enterochromaffin-like cell: an acid update. Dig Surg 15 (1998) 209-217
14. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315 (1985) 115-122
15. Rane S., Dubus P., Mettus R., et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet 22 (1999) 44-52
16. Franklin D., Godfrey V., O'Brien D., et al. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol 20 (2000) 6147-6158
17. Yang H., Kutok J., Lee N., et al. Targeted expression of human MYCN selectively causes pancreatic neuroendocrine tumors in transgenic zebrafish. Cancer Res 64 (2004) 7256-7262
18. Nilsson O., Wangberg B., Johansson L., et al. Praomys (Mastomys) natalensis: a model for gastric carcinoid formation. Yale J Biol Med 65 (1992) 741-751
19. Fossmark R., Martinsen T., Bakkelund K., et al. ECL-cell derived gastric cancer in male cotton rats dosed with the H2-blocker loxtidine. Cancer Res 64 (2004) 3687-3693
20. Bertolino P., Tong W., Herrera P., et al. Pancreatic beta-cell-specific ablation of the multiple endocrine neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma development in mice. Cancer Res 63 (2003) 4836-4841
21. Crabtree J., Scacheri P., Ward J., et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci USA 98 (2001) 1118-1123
22. Biondi C., Gartside M., Waring P., et al. Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues. Mol Cell Biol 24 (2004) 3125-3131
23. Parekh D., Ishizuka J., Townsend Jr. C., et al. Characterization of a human pancreatic carcinoid in vitro: morphology, amine and peptide storage, and secretion. Pancreas 9 (1994) 83-90
24. Kolby L., Bernhardt P., Ahlman H., et al. A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. Am J Pathol 158 (2001) 745-755
25. Leotlela P., Jauch A., Holtgreve-Grez H., and Thakker R. Genetics of neuroendocrine and carcinoid tumours. Endocr Relat Cancer 10 (2003) 437-450
26. Modlin I., Kidd M., Latich I., et al. Current status of gastrointestinal carcinoids. Gastroenterology 128 (2005) 1717-1751
27. Tonnies H., Toliat M., Ramel C., et al. Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation. Gut 48 (2001) 536-541
28. Thakker R. Multiple endocrine neoplasia type 1. In: DeGroot L., and Jamesson J. (Eds). Endocrinology. 5th edn. (2006), Elsevier Saunders, Philadelphia, USA 3509-3521
29. Lollgen R., Hessman O., Szabo E., et al. Chromosome 18 deletions are common events in classical midgut carcinoid tumors. Int J Cancer 92 (2001) 812-815
30. In: DeLellis R., Lloyd R., Heitz P., and Eng C. (Eds). World Health Organization classification of tumours, pathology and genetics of tumours of endocrine organs (2004), IARC Press, Lyon
31. Anlauf M., Perren A., Meyer C., et al. Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. Gastroenterology 128 (2005) 1187-1198
32. Kaltsas G., Besser G., and Grossman A. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25 (2004) 458-511
33. Eriksson B., Oberg K., and Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion 62 suppl 1 (2000) 33-38
34. Moller J., Pellikka P., Bernheim A., et al. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation 112 (2005) 3320-3327
35. Berna M., Hoffmann K., Long S., et al. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 85 (2006) 331-364
36. Stridsberg M., Oberg K., Li Q., et al. Measurement of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 144 (1995) 49-59
37. Kloppel G., Perren A., and Heitz P. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 1014 (2004) 13-27
38. Lloyd R. Practical markers used in the diagnosis of neuroendocrine tumors. Endocr Pathol 14 (2003) 293-301
39. Saqi A., Alexis D., Remotti F., and Bhagat G. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am J Clin Pathol 123 (2005) 394-404
40. Gastrointestinal carcinoid tumours. In: Modlin I., Gustafsson B., and Kidd M. (Eds). Advances in digestive disease (2007), AGA Institute Press, Bethesda, MD 203-218
41. Anderson M., Carpenter S., Thompson N., et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 95 (2000) 2271-2277
42. Gibril F., and Jensen R. Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours. Dig Liver Dis 36 suppl 1 (2004) S106-S120
43. Gibril F., Reynolds J., Doppman J., et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 125 (1996) 26-34
44. Adams S., Baum R., Rink T., et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 25 (1998) 79-83
45. Koopmans K., de Vries E., Kema I., et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 7 (2006) 728-734
46. Montravers F., Grahek D., Kerrou K., et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?. J Nucl Med 47 (2006) 1455-1462
47. Orlefors H., Sundin A., Garske U., et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 90 (2005) 3392-3400
48. Koukouraki S., Strauss L., Georgoulias V., et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 33 (2006) 460-466
49. D'Onofrio M., Zamboni G., Faccioli N., et al. Ultrasonography of the pancreas. 4. Contrast-enhanced imaging. Abdom Imaging 32 (2007) 171-181
50. Hyslop W., Balci N., and Semelka R. Future horizons in MR imaging. Magn Reson Imaging Clin N Am 13 (2005) 211-224
51. Funovics M., Kapeller B., Hoeller C., et al. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging 22 (2004) 843-850
52. Thorek D., Chen A., Czupryna J., and Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng 34 (2006) 23-38
53. van Tuyl S., van Noorden J., Timmer R., et al. Detection of small-bowel neuroendocrine tumors by video capsule endoscopy. Gastrointest Endosc 64 (2006) 66-72
54. Yamaguchi T., Manabe N., Tanaka S., et al. Multiple carcinoid tumors of the ileum preoperatively diagnosed by enteroscopy with the double-balloon technique. Gastrointest Endosc 62 (2005) 315-318
55. Plockinger U., Rindi G., Arnold R., et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80 (2004) 394-424
56. Norton J. Surgery for primary pancreatic neuroendocrine tumors. J Gastrointest Surg 10 (2006) 327-331
57. Norton J. Endocrine tumours of the gastrointestinal tract. Surgical treatment of neuroendocrine metastases. Best Pract Res Clin Gastroenterol 19 (2005) 577-583
58. Ahlman H. Surgical treatment of carcinoid tumours of the stomach and small intestine. Ital J Gastroenterol Hepatol 31 suppl 2 (1999) S198-S201
59. Sarmiento J., Farnell M., Que F., and Nagorney D. Pancreaticoduodenectomy for islet cell tumors of the head of the pancreas: long-term survival analysis. World J Surg 26 (2002) 1267-1271
60. Norton J., Alexander H., Fraker D., et al. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome?. Ann Surg 239 (2004) 617-625
61. Norton J., and Jensen R. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 240 (2004) 757-773
62. van Vilsteren F., Baskin-Bey E., Nagorney D., et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl 12 (2006) 448-456
63. Benjegard S., Forssell-Aronsson E., Wangberg B., et al. Intraoperative tumour detection using 111In-DTPA-D-Phe1-octreotide and a scintillation detector. Eur J Nucl Med 28 (2001) 1456-1462
64. O'Toole D., and Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 19 (2005) 585-594
65. Roche A., Girish B., de Baere T., et al. Prognostic factors for chemoembolization in liver metastasis from endocrine tumors. Hepatogastroenterology 51 (2004) 1751-1756
66. Chung J., Park J., Han J., et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 198 (1996) 33-40
67. Mazzaglia P., Berber E., Milas M., and Siperstein A. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 142 (2007) 10-19
68. Shojamanesh H., Gibril F., Louie A., et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 94 (2002) 331-343
69. Panzuto F., Di Fonzo M., Iannicelli E., et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol 17 (2006) 461-466
70. Kolby L., Persson G., Franzen S., and Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 90 (2003) 687-693
71. Kouvaraki M., Ajani J., Hoff P., et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22 (2004) 4762-4771
72. Yao J., Ng C., Hoff P., et al. Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab. Proc Am Soc Clin Oncol 23 (2005) 309 (abstr).
73. Kulke M., Henz J., Meropolo N., et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). Proc Am Soc Clin Oncol 23 (2005) 310 (abstr).
74. Duran I., Kortmansky J., Singh D., et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95 (2006) 1148-1154
75. Yao J., Phan A., Jacobs C., et al. Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET). Proc Am Soc Clin Oncol Gastro Cancers Symp (2006) abstr 178.
76. Therasse P., Arbuck S., Eisenhauer E., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
77. Forrer F., Valkema R., Kwekkeboom D., et al. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 21 (2007) 111-129
78. Lepage C., Rachet B., and Coleman M. Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. Gastroenterology 132 (2007) 899-904